Longitudinal TNFR1 and TNFR2 and Kidney Outcomes: Results from AASK and VA NEPHRON-D.
AASK (African American Study of Kidney Disease and Hypertension)
chronic inflammation
chronic kidney disease
diabetes mellitus
end-stage kidney disease
renal function decline
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
03
06
2021
accepted:
23
02
2022
pubmed:
23
3
2022
medline:
4
5
2022
entrez:
22
3
2022
Statut:
ppublish
Résumé
Higher baseline levels of soluble TNF receptors (TNFR1 and TNFR2) have been associated with progressive CKD. Whether longitudinal changes in these biomarkers of inflammation are also associated with worse kidney outcomes has been less studied. We evaluated associations of longitudinal changes in TNFR1 and TNFR2 with ESKD in the African American Study of Kidney Disease and Hypertension (AASK; 38% female; 0% diabetes) and kidney function decline (first occurrence of ≥30 ml/min per 1.73 m There were 129 ESKD events over a median of 7.0 years in AASK ( Among individuals with and without diabetes, longitudinal increases in TNFR1 and TNFR2 were each associated with progressive CKD, independent of initial biomarker level and kidney function.
Sections du résumé
BACKGROUND
Higher baseline levels of soluble TNF receptors (TNFR1 and TNFR2) have been associated with progressive CKD. Whether longitudinal changes in these biomarkers of inflammation are also associated with worse kidney outcomes has been less studied.
METHODS
We evaluated associations of longitudinal changes in TNFR1 and TNFR2 with ESKD in the African American Study of Kidney Disease and Hypertension (AASK; 38% female; 0% diabetes) and kidney function decline (first occurrence of ≥30 ml/min per 1.73 m
RESULTS
There were 129 ESKD events over a median of 7.0 years in AASK (
CONCLUSIONS
Among individuals with and without diabetes, longitudinal increases in TNFR1 and TNFR2 were each associated with progressive CKD, independent of initial biomarker level and kidney function.
Identifiants
pubmed: 35314457
pii: 00001751-202205000-00014
doi: 10.1681/ASN.2021060735
pmc: PMC9063900
doi:
Substances chimiques
Biomarkers
0
Receptors, Tumor Necrosis Factor, Type I
0
Receptors, Tumor Necrosis Factor, Type II
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
996-1010Subventions
Organisme : NIDDK NIH HHS
ID : K08 DK117068
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK040561
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK079310
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK108803
Pays : United States
Investigateurs
Vasan S Ramachandran
(VS)
Joseph Massaro
(J)
Clary Clish
(C)
Jeffrey Schelling
(J)
Michelle Denburg
(M)
Susan Furth
(S)
Bradley Warady
(B)
Joseph Bonventre
(J)
Sushrut Waikar
(S)
Gearoid McMahon
(G)
Venkata Sabbisetti
(V)
Josef Coresh
(J)
Morgan Grams
(M)
Casey Rebholz
(C)
Alison Abraham
(A)
Adrienne Tin
(A)
Chirag Parikh
(C)
Jon Klein
(J)
Steven Coca
(S)
Bart S Ferket
(BS)
Girish N Nadkarni
(GN)
Eugene Rhee
(E)
Paul L Kimmel
(PL)
Daniel Gossett
(D)
Brad Rovin
(B)
Michael G Shlipak
(MG)
M Sarnak
(M)
Andrew S Levey
(AS)
Lesley A Inker
(LA)
Meredith Foster
(M)
Orlando M Gutiérrez
(OM)
Joachim Ix
(J)
Ruth Dubin
(R)
Jesse Seegmiller
(J)
Tom Hostetter
(T)
Rajat Deo
(R)
Harold I Feldman
(HI)
Amanda Anderson
(A)
Theodore Mifflin
(T)
Dawei Xie
(D)
Haochang Shou
(H)
Shawn Ballard
(S)
Krista Whitehead
(K)
Heather Collins
(H)
Jason Greenberg
(J)
Peter Ganz
(P)
Informations de copyright
Copyright © 2022 by the American Society of Nephrology.
Références
Centers for Disease Control and Prevention: Chronic kidney disease in the United States, 2021, Atlanta, GA, US Department of Health and Human Services, Centers for Disease Control and Prevention, 2021
Chen TK, Knicely DH, Grams ME: Chronic kidney disease diagnosis and management: A review. JAMA 322: 1294–1304, 2019
Chen TK, Sperati CJ, Thavarajah S, Grams ME: Reducing kidney function decline in patients with CKD: Core curriculum 2021. Am J Kidney Dis 77: 969–983, 2021
United States Renal Data System: 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2020
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Available at https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf . Accessed March 11, 2022
Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al.; CKD Prognosis Consortium: Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 3: 514–525, 2015
Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al.: Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311: 2518–2531, 2014
Waikar SS, Rebholz CM, Zheng Z, Hurwitz S, Hsu CY, Feldman HI, et al.; Chronic Kidney Disease Biomarkers Consortium Investigators: Biological variability of estimated GFR and albuminuria in CKD. Am J Kidney Dis 72: 538–546, 2018
Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al.: Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis 75: 84–104, 2020
Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, et al.: Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 23: 516–524, 2012
Coca SG, Nadkarni GN, Huang Y, Moledina DG, Rao V, Zhang J, et al.: Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J Am Soc Nephrol 28: 2786–2793, 2017
Chen TK, Estrella MM, Appel LJ, Coresh J, Luo S, Reiser J, et al.: Biomarkers of immune activation and incident kidney failure with replacement therapy: Findings from the African American Study of Kidney Disease and Hypertension. Am J Kidney Dis 78: 75–84.e1, 2021
Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, et al.: Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 23: 507–515, 2012
Pavkov ME, Nelson RG, Knowler WC, Cheng Y, Krolewski AS, Niewczas MA: Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int 87: 812–819, 2015
Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al.; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421–2431, 2002
Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, et al.; AASK Collaborative Research Group: Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363: 918–929, 2010
Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al.; VA NEPHRON-D Investigators: Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369: 1892–1903, 2013
Gassman JJ, Greene T, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, et al.: Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 14[Suppl 2]: S154–S165, 2003
Toto RD, Greene T, Hebert LA, Hiremath L, Lea JP, Lewis JB, et al.; AASK Collaborative Research Group: Relationship between body mass index and proteinuria in hypertensive nephrosclerosis: Results from the African American Study of Kidney Disease and Hypertension (AASK) cohort. Am J Kidney Dis 56: 896–906, 2010
Chen TK, Tin A, Peralta CA, Appel LJ, Choi MJ, Lipkowitz MS, et al.: APOL1 risk variants, incident proteinuria, and subsequent eGFR decline in Blacks with hypertension-attributed CKD. Clin J Am Soc Nephrol 12: 1771–1777, 2017
Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, et al.; AASK Study Investigators; CRIC Study Investigators: APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 369: 2183–2196, 2013
Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al.: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841–845, 2010
Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, et al.: Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128: 345–350, 2010
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130: 461–470, 1999
Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 94: 496–509, 1999
Sen T, Li J, Neuen BL, Neal B, Arnott C, Parikh CR, et al.: Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia 64: 2147–2158, 2021
Grams ME, Sang Y, Ballew SH, Matsushita K, Astor BC, Carrero JJ, et al.: Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: An individual participant meta-analysis of observational data. J Am Soc Nephrol 30: 1746–1755, 2019
Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, et al.: GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol 30: 1735–1745, 2019
Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al.; African American Study of Kidney Disease and Hypertension (AASK) Study Group: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285: 2719–2728, 2001
Bemelmans MHA, van Tits LJH, Buurman WA: Tumor necrosis factor: Function, release and clearance. Crit Rev Immunol 37: 249–259, 2017
Speeckaert MM, Speeckaert R, Laute M, Vanholder R, Delanghe JR: Tumor necrosis factor receptors: Biology and therapeutic potential in kidney diseases. Am J Nephrol 36: 261–270, 2012
Vanamee ES, Faustman DL: Structural principles of tumor necrosis factor superfamily signaling. Sci Signal 11: 11, 2018
Bhatraju PK, Zelnick LR, Shlipak M, Katz R, Kestenbaum B: Association of soluble TNFR-1 concentrations with long-term decline in kidney function: The multi-ethnic study of atherosclerosis. J Am Soc Nephrol 29: 2713–2721, 2018